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Letters to the Editorexposed to 0.9 T showed a 7% in-
crease in volume. Shortening was re-
duced by approximately 30% after
recovery in both 0.6 T and 0.9 T
groups. Thus, despite a 23% differ-
ence in size between groups, there
was no difference in function.3 This ar-
gues against a direct relationship be-
tween edema and dysfunction.
In Dr Lawton’s study, function was
measured only in the recovery phase,
when cardiomyocytes had returned to
their normal size and not during the
time in which cells were swollen.
Yet, in the clinical context, edema
and dysfunction occur concurrently,
and this has largely been the basis for
a causal association to be drawn. Data
we present from Langendorff-based
analyses show only a limited associa-
tion exists. An increase in water con-
tent of 3.3% was associated with
a 9% reduction in developed pressure,
which in this model is a modest de-
cline. Developed pressure was stable
for up to 20 minutes of hypotonic expo-
sure and returned to baseline with iso-
tonic reperfusion.1 Our surgical
modeling suggests that swelling is tol-
erated for several hours without func-
tional effect. Thus, it is unlikely that
the duration of hypotonic exposure,
a further methodologic difference be-
tween our studies, was responsible for
the lack of edema-related dysfunction.
It must be acknowledged that exper-
imental separation of tonicity from is-
chemia, removing osmotic influences
of the interstitial and vascular com-
partments, is highly artificial. Future
use of human myocytes in this model
will also be subject to the same ca-
veats. It is likely that the dogma relat-
ing edema to dysfunction confuses
extracellular water accumulation, as
a result of capillary leak and renal ef-
fects of lower cardiac output, with in-
tracellular water accumulation,
which is well tolerated by the heart
and quickly resolves through trans-
membrane water exchange.4,5
The most credible interpretation of
data from both our groups is that the
swollen heart of ‘‘myocardial edema’’The Journalas observed by surgeons after long
neonatal cardiac surgery actually
represents the effects of myocardial
dysfunction with the ventricles work-
ing at a higher intracavitary volume
and reduced fractional shortening,
almost all of which can be attributed
to the effects of ischemia and reperfu-
sion. The water content of the myocar-
dium itself may be increased by a few
percentage points, and this contributes
to a decrease in cardiac performance
by a similar amount.
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STENT-GRAFT INFECTION IN
THE TREATMENT OF
AORTOBRONCHIAL
FISTULAS?
To the Editor:
A recent article by Hacker and col-
leagues1 describes a single case report
of aortobronchial fistula (ABF) in a pa-
tient who was successfully treated (27
years ago) for isthmic posttraumaticof Thoracic and Cardiovascular Surgepseudoaneurysm by placement of tho-
racic endoprosthesis. The authors con-
clude by saying that ‘‘endovascular
intervention and stent grafting are fea-
sible and should be the first option in
the treatment of ABFs.’’
We agree that ABF is a rare and fatal
disease and most frequently associated
with previous cardiac, vascular, or
thoracic surgery. Surgical treatment
is still characterized by high rates of
mortality and morbidity. Our article2
showed that it is not possible to identify
a half-accurate diagnostic instrument:
angiography, bronchoscopy, and trans-
esophageal echocardiography are asso-
ciated with a high rate of complications,
including fatal hemorrhage. Findings
suggestive of ABF on computed to-
mography scan include pseudoaneur-
ysm, aortic anatomy abnormalities,
lung parenchyma consolidation, and
compression of bronchial tree.
Conventional open surgical correc-
tion involves a thoracotomy and has
fairly high morbidity and mortality be-
cause of difficult operative dissection
associated with reoperative surgery;
in addition, patients may have severe
comorbidities and present in rather
poor health. Endovascular stent graft-
ing provides a safe and reliable method
to treat ABF.
One potential life-threatening compli-
cation is stent-graft infection; however,
in our experience, no signs of infections
were detected by postoperative scintig-
raphy with labeled leukocytes.
It is unclear why the infection rate
for endovascular repair is minimal,
but the stent graft remains in the center
of the aneurysm sac well away from
the actual fistula and source of contam-
ination. Perhaps because there is
minimal tissue trauma associated
with the deployment of the stent graft,
as opposed to open surgical repair, the
excluded aneurysmal or pseudo-aneu-
rysmal cavity is less likely to become
contaminated or infected.
Postoperative antibiotic treatment
differs completely among the various
authors, both with regard to the antibi-
otic (cephalosporin, vancomycin,ry c Volume 139, Number 2 511
Letters to the Editorantifungal) and the duration of therapy
(lifelong antibiotic therapy?).
In our opinion, the open questions
remain: (1) Which antibiotic therapy
should be performed in patients with
ABF treated with thoracic endovascu-
lar aneurysm repair? (2) How long
should antibiotic therapy be continued?
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Bozzani and colleagues1 state that
surgical correction of an aortobron-
chial fistula, particularly open cor-
rection of a thoracic aneurysm,
carries a fairly high postoperative
incidence of stent-graft infection.
To the contrary, minimal infection
rates were observed after endovascu-
lar stent placement. The authors
question whether antibiotic therapy
should be administrated after this
minimally invasive operational
procedure.1,2 There is scarce litera-
ture on immunologic consequences
after stent implantation in humans.
According to immunologic data
obtained from patients undergoing
heart operations with cardiopulmo-
nary support and abdominal surgery,
any operation performed in humans
induces a state of immune suppression
in vivo. Therefore, patients undergoing
heart surgery (cardiopulmonary support)512 The Journal of Thoracic and Cshould receive aggressive 5-day antibi-
otic treatment in accordance with the in-
sight of an induced ‘‘systemic immune
suppression’’ after heart surgery.3,4 In
regard to the ongoing discussion of anti-
biotic treatment after endovascular stent
implantation, the following approach
seems to be feasible. Studies have to
be initiated to investigate the immuno-
logic consequence of open and endovas-
cular stent implantation in humans (eg,
abdominal aorta aneurysm repair,
open, closed), and ‘‘yes,’’ antibiotic
treatment should be applied for 4 to 5
days after endovascular stent placement
to potentially ‘‘prohibit’’ pain from in-
fection (local, systemic) in patients.
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TECHNIQUE TO CARBON
DIOXIDE DE-AIRING IN OPEN
CARDIAC OPERATIONS?
To the Editor:
In a recent study Al-Rashidi and as-
sociates1 concluded that ‘‘bilateral .ardiovascular Surgery c February 2010pulmonary collapse and successive
filling of the lungs with . concomi-
tant increase in mechanical ventilation
during de-airing of the left side of the
heart significantly reduces the number
of systemic MES [microembolic sig-
nals]. and. air emboli.’’
Inasmuch as the study’s limitations
were not mentioned, we would like
to discuss a few:
1. Inasmuch as the patients were alter-
nately allotted to control and study
groups, the principle of randomiza-
tion was ignored. Moreover, the
principle of unbiased assessment
was also compromised inasmuch
as the single surgeon, who actively
followed the degree of de-airing via
transesophageal echocardiography
(TEE) during the surgical de-airing
maneuvers before the end of car-
diopulmonary bypass (CPB), thus
participated in the evaluation of
the technique, which he himself
had proposed.
2. The authors enumerate 9 exclusion
criteria, including accidental open-
ing of the pleural cavity and
chronic obstructive lung disease,
although all operations were per-
formed by one highly experienced
surgeon. Consequently, the gener-
alizability of the results cannot but
be very limited.
3. According to the Methods section,
TEE and transcranial Doppler
(TCD) measurements were only
performed after CPB. However, in
the Results section, the authors
make comparisons with the number
of MES before the end of CBP.
Moreover, ‘‘The aortic root was
de-aired’’ before release of the
crossclamp only in the study group.
4. The possible risks of a left ventricu-
lar vent inserted through the apex of
the heart (eg, bleeding and arrhyth-
mias), a prerequisite of the tech-
nique, have not been mentioned.
5. In contrast to common practice as
well as the study group, the con-
trol group patients had their
lungs ventilated continuously during
